GIST
GIST
Advertisement
Emily MenendezGIST | April 19, 2024
A study compared the long-term survival outcomes of endoscopic and surgical treatment for GISTs ranging from 5 to 10 cm.
Read More
Emily MenendezGIST | March 21, 2024
Patients diagnosed with GISTs can face a higher risk of additional malignancies, including genitourinary cancers.
Katy MarshallGIST | March 6, 2024
Ripretinib has previously been identified as an effective inhibitor of secondary KIT mutations while in the AL.
Katy MarshallGIST | February 29, 2024
Patients with moderate- or high-risk GIST receive adjuvant imatinib therapy following surgical resection.
Emily MenendezGIST | March 1, 2024
While imatinib is considered standard-of-care, there is a lack of clinical data for the treatment among elderly patients.
Zachary BessetteGIST | February 22, 2024
Surgical treatment combined with targeted therapy may improve OS and CSS in patients with GIST-SLM.
Zachary BessetteGIST | February 22, 2024
A final overall survival and updated safety analysis from the phase 3 INTRIGUE study.
Kerri FitzgeraldGIST | February 29, 2024
Topline results from the pivotal phase III INVICTUS trial showed that the novel drug ripretinib improved ...
Advertisement
Advertisement
Advertisement
Latest News

April 24, 2024